marketcaparena
Search

    MAIA

    MAIA Biotechnology, Inc.

    Company overview

    Market capitalization
    $71.77M
    Employees
    13
    Latest publication
    2026-09-29
    About MAIA Biotechnology, Inc.

    MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue0USD0USD0USD0USD0USD0USD0USD0USD
    Research Development5,639,660USD3,525,097USD1,881,644USD6,357,290USD3,110,867USD3,197,532USD2,969,084USD2,667,170USD
    General And Administrative Expenses2,677,591USD———————
    Total Operating Expenses8,317,251USD6,949,929USD4,317,272USD9,360,926USD5,166,058USD5,425,431USD5,004,604USD4,188,468USD
    Operating Income-8,317,251USD-6,949,929USD-4,317,272USD-9,360,926USD-5,166,058USD-5,425,431USD-5,004,604USD-4,188,468USD
    Total Other Income Expense Net373,664USD580,277USD688,510USD457,737USD-180,905USD908,172USD1,432,666USD1,452,481USD
    Interest Income236,320USD111,757USD73,648USD78,426USD79,697USD82,183USD79,784USD106,082USD
    Net Income-7,943,587USD-6,369,652USD-3,628,762USD-8,903,189USD-5,346,963USD-4,517,259USD-3,571,938USD-2,735,987USD
    Selling General Administrative—3,424,832USD2,435,628USD3,003,636USD2,055,191USD2,227,899USD2,035,520USD1,521,298USD
    Net Interest Income—111,757USD73,648USD78,426USD79,697USD82,183USD79,812USD105,997USD
    Income Before Tax—-6,369,652USD-3,628,762USD-8,903,189USD-5,346,963USD-4,517,259USD-3,571,938USD-2,735,987USD
    Net Income From Continuing Ops—-6,369,652USD-3,628,762USD-8,903,189USD-5,346,963USD-4,517,259USD-3,571,938USD-2,735,987USD
    Ebitda—-6,949,929USD-3,628,762USD457,737USD-5,166,058USD-5,425,431USD-3,571,966USD-2,735,902USD
    Interest Expense——0USD0USD——28USD85USD
    Ebit——-24,250,191,322USD-8,903,189USD-10,332,116USD-10,850,000USD-3,571,966USD-2,735,902USD
    Depreciation And Amortization——-9,360,926USD9,360,926USD5,166,058USD5,425,000USD5,004,604USD1,453,000USD
    Income Tax Expense——————-28,107USD—
    Source0001493152-26-036764DeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USD
    Total Revenue0USD0USD0USD0USD0USD0USD—
    Research Development14,547,332,000USD10,009,229USD11,112,257USD8,933,314USD3,453,130USD1,412,409USD1,911,882USD
    Selling General Administrative9,722,354,000USD6,947,981USD9,070,124USD6,143,527USD4,289,831USD5,563,192USD5,009,474USD
    Unclassified Operating Expenses-24,245,416,314USD——1,099,360USD———
    Total Operating Expenses24,269,686USD16,957,210USD20,182,381USD16,176,201USD7,786,627USD6,975,601USD6,921,356USD
    Operating Income-24,269,686USD-16,957,210USD-20,182,381USD-16,176,201USD-7,786,627USD-6,975,601USD-6,921,356USD
    Interest Income313,954USD318,367USD34,490USD1,870USD2,012USD679USD—
    Interest Expense0USD57USD6,863USD6,967USD827,539USD31,547USD0USD
    Net Interest Income313,954USD318,310USD27,627USD-5,097USD-825,527USD-31,547USD—
    Income Before Tax-22,396,172USD-23,254,656USD-19,772,905USD-15,769,279USD-12,578,211USD-6,959,248USD-6,921,114USD
    Net Income-22,396,172USD-23,254,656USD-19,772,905USD-15,769,279USD-12,503,880USD-6,636,660USD-6,492,782USD
    Net Income From Continuing Ops-22,396,172USD-23,254,656USD-19,772,905USD-15,769,279USD-12,578,211USD-6,959,248USD—
    Ebitda-24,269,686USD-23,254,599USD-19,766,042USD-15,762,312USD-11,750,672USD-6,975,000USD242USD
    Total Other Income Expense Net1,873,514USD-6,297,446USD409,476USD406,922USD-4,791,584USD16,353USD242USD
    Income Tax Expense—-79,954USD-176,719USD36,689USD707,530USD-291,000USD-435,000USD
    Ebit—-23,254,713USD-20,182,381USD-16,176,201USD-15,528,000USD-13,950,523USD-6,920,758USD
    Depreciation And Amortization—6,297,503USD2USD1USD7,787,000USD6,975,601USD6,921,356USD
    Minority Interest———0USD74,331USD322,588USD—
    Net Income Applicable To Common Shares————-12,503,880USD-6,636,660USD-6,492,782USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets28,240,171USD35,322,645USD9,704,656USD11,782,021USD11,045,854USD11,864,652USD10,155,279USD9,242,842USD
    Cash And Equivalents27,595,831USD———————
    Total Current Assets28,237,371USD35,315,127USD9,701,856USD11,754,936USD11,043,054USD11,861,852USD10,152,479USD9,240,042USD
    Other Current Assets641,540USD902,017USD1,043,825USD863,200USD816,260USD920,472USD473,834USD495,650USD
    Other Non Current Assets2,800USD———————
    Total Liabilities7,565,161USD———————
    Total Current Liabilities6,257,892USD6,322,437USD5,836,398USD9,994,444USD5,043,952USD5,057,511USD3,830,038USD3,608,899USD
    Other Current Liabilities3,419,240USD———————
    Other Non Current Liabilities1,307,269USD———————
    Total Stockholder Equity20,675,010USD27,762,768USD2,375,863USD41,670USD3,876,684USD4,942,525USD3,634,636USD1,618,591USD
    Accounts Payable2,838,652USD2,983,058USD2,039,000USD3,175,641USD1,723,163USD1,841,369USD1,512,436USD1,152,055USD
    Common Stock6,082USD6,068USD3,863USD3,446USD3,182USD2,959USD2,616USD2,397USD
    Retained Earnings-123,944,244USD-116,000,657USD-109,631,005USD-106,002,244USD-97,099,055USD-91,752,092USD-87,234,833USD-83,662,895USD
    Total Liab—7,559,877USD7,328,793USD11,740,351USD7,169,170USD6,922,127USD6,520,643USD7,624,251USD
    Other Current Liab—3,339,379USD5,834,359,000USD6,818,803USD3,320,789USD3,216,142USD2,317,602USD2,456,844USD
    Capital Stock—6,068USD3,863USD3,446USD3,182USD2,959USD2,616USD2,397USD
    Cash—34,413,110USD8,658,031USD10,891,736USD10,144,522USD10,863,296USD9,601,298USD8,690,784USD
    Cash And Short Term Investments—34,413,110USD8,658,031USD10,891,736USD10,144,522USD10,863,296USD9,601,298USD8,690,784USD
    Net Debt—-34,413,110USD-8,658,031USD-10,891,736USD-10,144,522USD-10,863,296USD-9,601,298USD-8,690,784USD
    Accumulated Other Comprehensive Income—-39,667USD-50,228USD-30,835USD-30,028USD-38,155USD-30,615USD-11,702USD
    Common Stock Shares Outstanding—32,115,000shares32,115,000shares33,202,000shares30,300,339shares27,697,000shares26,158,000shares23,895,000shares
    Non Current Assets Total—7,518USD2,800,000USD27,085USD2,800USD2,800USD2,800USD2,800USD
    Non Current Liabilities Total—1,237,440USD1,492,395USD1,745,907USD2,125,218USD1,864,616USD2,690,605USD4,015,352USD
    Non Currrent Assets Other—7,518USD2,800,000USD27,085USD2,800USD2,800USD2,800USD2,800USD
    Net Working Capital—28,992,690USD3,865,458USD1,760,492USD5,999,102USD6,804,341USD6,322,441USD5,631,143USD
    Unclassified Non Current Liabilities—1,237,440USD1,492,395USD1,745,907USD2,125,218USD1,864,616USD2,690,605USD4,015,352USD
    Unclassified Equity—143,790,956USD112,049,370USD106,067,857USD100,999,403USD96,726,854USD90,894,852USD85,288,394USD
    Unclassified Current Liabilities——-5,830,561,602USD—————
    Net Receivables————82,272USD78,084USD77,347USD53,608USD
    Source0001493152-26-036764DeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USD
    Total Assets10,155,279USD7,566,852USD12,022,040USD11,327,199USD746,505USD1,734,529USD
    Other Current Assets473,834USD268,677USD554,321USD98,203USD83,048USD24,964USD
    Total Liab6,520,643USD7,089,341USD3,514,247USD2,145,996USD2,362,805USD409,737USD
    Total Stockholder Equity3,634,636USD477,511USD8,507,793USD9,181,203USD-3,336,087USD-172,867USD
    Other Current Liab2,317,602USD3,298,607USD2,103,401USD1,185,595USD1,506,905USD180,377USD
    Common Stock2,616USD1,699USD1,096USD758USD443USD442USD
    Capital Stock2,616USD1,699USD1,096USD758USD443USD—
    Retained Earnings-87,234,833USD-63,980,177USD-44,207,272USD-28,437,993USD-15,934,113USD-9,297,453USD
    Cash9,601,298USD7,150,695USD10,950,927USD10,574,292USD663,457USD1,709,565USD
    Cash And Short Term Investments9,601,298USD7,150,695USD10,950,927USD10,574,292USD663,457USD1,709,565USD
    Total Current Assets10,152,479USD7,564,052USD11,808,037USD10,672,495USD746,505USD1,734,529USD
    Total Current Liabilities3,830,038USD4,937,153USD3,268,906USD2,145,996USD1,693,744USD374,565USD
    Net Debt-9,601,298USD-7,150,695USD-10,950,927USD-10,574,292USD-199,703USD-1,675,393USD
    Net Receivables77,347USD144,680USD302,789USD43,666USD——
    Accounts Payable1,512,436USD1,638,546USD1,165,505USD960,401USD154,886USD169,188USD
    Accumulated Other Comprehensive Income-30,615USD-16,260USD-15,973USD—-2,002USD-104,402USD
    Common Stock Shares Outstanding22,197,517shares13,262,000shares9,277,000shares10,635,904shares10,636,000shares10,636,000shares
    Non Current Assets Total2,800USD2,800USD214,003USD654,704USD0USD—
    Non Current Liabilities Total2,690,605USD2,152,188USD245,341USD960,401USD669,061USD35,172USD
    Non Currrent Assets Other2,800USD2,800USD214,003USD654,704USD——
    Net Working Capital6,322,441USD2,626,899USD8,539,131USD8,526,499USD-947,239USD—
    Unclassified Non Current Liabilities2,690,605USD2,152,188USD————
    Unclassified Equity90,894,852USD64,470,550USD52,728,846USD37,617,680USD12,599,142USD9,228,546USD
    Deferred Long Term Liab———651,582USD——
    Other Assets———654,704USD——
    Current Deferred Revenue———111,271USD—1USD
    Short Term Debt———111,271USD31,953USD25,000USD
    Inventory———-43,666USD——
    Net Tangible Assets———9,181,203USD-3,336,087USD-172,867USD
    Other Liab————237,260USD26,000USD
    Short Long Term Debt————31,953USD—
    Short Long Term Debt Total————463,754USD34,172USD
    Long Term Debt————431,801USD—
    Non Current Liabilities Other————25,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-6,369,652USD-3,628,762USD-8,903,188USD-5,346,963USD-4,517,259USD-3,571,938USD-2,735,987USD-8,879,276USD
    Stock Based Compensation650,024USD810,796USD646,900USD802,484USD371,472USD693,443USD455,388USD413,948USD
    Other Non Cash Items438,720USD115,667USD-191,998USD322,923USD-825,989USD-1,256,757USD-1,231,286USD5,170,445USD
    Change In Working Capital619,604USD-4,318,172USD4,961,770USD86,219USD769,502USD227,077USD-12,830USD-1,389,888USD
    Total Cash From Operating Activities-5,311,328USD-7,020,471USD-3,486,516USD-4,135,337USD-4,202,274USD-3,908,175USD-3,524,715USD-4,684,771USD
    Capital Expenditures-2USD-4USD0USD-4USD-4USD-5USD-1USD-1USD
    Free Cash Flow-5,311,330USD-7,020,471USD-3,486,516USD-4,135,337USD-4,202,274USD-3,908,175USD-3,524,715USD-4,684,771USD
    Total Cash From Financing Activities31,052,321USD4,802,372USD4,234,769USD3,408,190USD5,461,216USD4,845,463USD626,819USD7,987,279USD
    Issuance Of Capital Stock33,008,813USD4,921,076USD3,779,251USD3,255,891USD5,665,040USD4,978,357USD660,437USD8,121,977USD
    Change In Cash25,755,079USD-2,233,705USD747,214USD-718,774USD1,261,998USD910,514USD-2,888,607USD3,307,942USD
    Begin Period Cash Flow8,658,031USD10,891,736USD10,144,522USD10,863,296USD9,601,298USD8,690,784USD11,579,391USD8,271,449USD
    End Period Cash Flow34,413,110USD8,658,031USD10,891,736USD10,144,522USD10,863,296USD9,601,298USD8,690,784USD11,579,391USD
    Other Cashflows From Financing Activities31,052,321USD-118,704USD-117,136USD-176,625USD-204,668USD-132,894USD-33,618USD-134,698USD
    Unclassified Financing Cash Flow-33,008,813USD———————
    Change To Account Receivables—80,410USD———-35,746USD129,201USD53,808USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USD
    Net Income-22,396,172USD-23,254,656USD-19,772,905USD-15,769,279USD-12,578,211USD-6,959,248USD-6,492,782USD
    Stock Based Compensation2,631,652USD1,912,744USD3,089,304USD2,319,427USD2,722,893USD3,888,968USD4,136,650USD
    Other Non Cash Items-579,397USD6,875,200USD526,531USD1,000,966USD4,606,676USD-28,025USD4,658,213USD
    Change To Account Receivables80,410USD56,805USD158,405USD-269,395USD———
    Change In Working Capital1,499,319USD-1,237,749USD3,086,054USD352,782USD1,125,746USD1,254,142USD269,457USD
    Total Cash From Operating Activities-18,844,598USD-15,704,461USD-13,071,016USD-12,096,104USD-4,122,896USD-1,844,163USD-1,565,112USD
    Capital Expenditures0USD0USD-4USD0USD0USD0USD-2USD
    Free Cash Flow-18,844,598USD-15,704,461USD-13,071,016USD-12,096,104USD-4,122,896USD-1,844,163USD-1,565,110USD
    Total Cash From Financing Activities17,906,547USD18,176,609USD9,270,901USD12,477,169USD14,033,731USD798,055USD2,222,305USD
    Issuance Of Capital Stock17,621,258USD18,754,708USD11,416,960USD13,973,560USD5,742,171USD50,000USD—
    Change In Cash-943,267USD2,450,603USD-3,800,232USD376,635USD9,910,835USD-1,046,108USD1,709,565USD
    Begin Period Cash Flow9,601,298USD7,150,695USD10,950,927USD10,574,292USD663,457USD1,709,565USD1,707,855USD
    End Period Cash Flow8,658,031USD9,601,298USD7,150,695USD10,950,927USD10,574,292USD663,457USD1,709,565USD
    Other Cashflows From Financing Activities-617,133USD-578,099USD-2,146,059USD-1,496,391USD860,427USD79,188USD124,999USD
    Change To Inventory———269,395USD———
    Net Borrowings———0USD7,431,133USD668,867USD35,000USD
    Change To Liabilities————805,516USD-2,304USD104,826USD
    Dividends Paid—————-58,212USD—
    Sale Purchase Of Stock—————-58,212USD—
    Total Cashflows From Investing Activities——————187,556USD
    Other Cashflows From Investing Activities——————187,556USD
    Unclassified Operating Cash Flow——————-4,136,650USD
    Unclassified Financing Cash Flow——————2,062,306USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    Active NIH SBIR Awards

    Period endPeriodValueUnitSource
    2026-06-30instant1countDisclosure

    THIO-101 Active International Clinical Sites

    Period endPeriodValueUnitSource
    2026-06-30instant44countDisclosure

    THIO-101 Active International Countries

    Period endPeriodValueUnitSource
    2026-06-30instant6countDisclosure

    THIO-101 Active U.S. Clinical Sites

    Period endPeriodValueUnitSource
    2026-06-30instant3countDisclosure

    THIO-101 Part C Disease Control Rate

    Period endPeriodValueUnitSource
    2026-06-30instant90.5percentDisclosure

    THIO-101 Part C Efficacy-Evaluable Patients

    Period endPeriodValueUnitSource
    2026-06-30instant21countDisclosure

    THIO-101 Part C Patients With Disease Control

    Period endPeriodValueUnitSource
    2026-06-30instant19countDisclosure

    THIO-101 Parts A and B Patients With Overall Survival Beyond Two Years

    Period endPeriodValueUnitSource
    2026-06-30instant8countDisclosure

    THIO-104 Activated Clinical Sites

    Period endPeriodValueUnitSource
    2026-06-30instant34countDisclosure

    THIO-104 Countries With Activated Sites

    Period endPeriodValueUnitSource
    2026-06-30instant6countDisclosure

    THIO-104 Patients Dosed

    Period endPeriodValueUnitSource
    2026-06-30instant29countDisclosure

    Revenue breakdown

    No revenue breakdown is currently published for this company.

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.